NCT06470763 2026-04-14
EXPAND-1
Anaveon AG
Phase 1/2 Active not recruiting
Clinical Trials
17 trialsNCT07182591 2026-03-20
A Study of DS5361b in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT06302426 2026-01-16
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
Phase 1 Recruiting
NCT06328673 2025-12-24
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
D2M Biotherapeutics Inc.
Phase 1 Active not recruiting
NCT05547321 2025-11-25
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
Phase 1 Recruiting
NCT05901285 2025-11-25
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
Phase 1 Recruiting
NCT05117476 2025-11-24
MICA
Cullinan Therapeutics Inc.
Phase 1 Active not recruiting
NCT05761223 2025-08-17
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
1ST Biotherapeutics, Inc.
Phase 1/2 Recruiting
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT06035744 2025-03-03
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Cullinan Therapeutics Inc.
Phase 1 Recruiting
NCT05438329 2025-02-27
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT05508100 2024-05-24
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
Immune-Onc Therapeutics
Phase 1 Completed
NCT04513067 2023-12-08
A Safety Study of YQ23 in Advanced Solid Tumors Patients
New Beta Innovation Limited
Phase 1 Terminated
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT03172819 2022-09-28
Special Combination of OBP-301 and Pembrolizumab
National Cancer Center Hospital East
Phase 1 Completed
NCT02553499 2019-11-04
MK-1248-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT03975036 2019-06-05
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
Henan Cancer Hospital
Phase 2/3 Unknown